STOCK TITAN
  1. Home
  2. News
  3. COYA

Coya Therapeutics Inc - COYA STOCK NEWS

Welcome to our dedicated news page for Coya Therapeutics (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coya Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coya Therapeutics's position in the market.

News
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces participation in the 3rd Annual ALS Drug Development Summit by President and Chief Medical Officer Dr. Fred Grossman. Dr. Grossman will lead a workshop on combination therapy approaches and present COYA 302, a dual mechanism biologic immunotherapy for ALS treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Rhea-AI Summary
Coya Therapeutics, Inc. (COYA) presents updated ALS biomarker data showing a high correlation between 4-HNE levels and ALS disease progression. The Company plans to validate 4-HNE as a new potential biomarker for ALS and include it in a planned Phase 2 trial with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
management conferences
-
News
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces positive clinical trial results for its biologics in treating neurodegenerative diseases, along with key corporate developments and financial results for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
earnings
News
Coya Therapeutics to Participate in BTIG Fireside Discussion
Rhea-AI Summary
Coya Therapeutics, Inc. announces that Dr. Stanley Appel and Dr. Fred Grossman will participate in a discussion hosted by BTIG Analyst Tom Shrader. They will talk about the role of regulatory T cells in treating neurodegenerative diseases, ALS survival data, and Coya's lead drug candidate COYA 302 for ALS, Parkinson's, Frontotemporal, and Alzheimer's diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
conferences
-
News
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
Rhea-AI Summary
4-Hydroxynonenal (4-HNE) levels strongly correlate with the rate of Amyotrophic Lateral Sclerosis (ALS) disease progression and patient survival, making it a potential biomarker for tracking treatment efficacy. Coya Therapeutics, Inc. (Nasdaq: COYA) presents promising biomarker data at the Society of Neuroimmune Pharmacology Conference, indicating the importance of 4-HNE in ALS pathophysiology and patient outcomes. The company plans to validate 4-HNE as a new biomarker for predicting disease progression and survival in ALS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
none
-
News
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
Rhea-AI Summary
Coya Therapeutics presents data demonstrating compromised Treg function and increased inflammatory markers in FTD patients. COYA 302 aims to restore Treg function and target inflammation in neurodegenerative diseases like FTD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
News
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces the presentation of data on chronic systemic inflammation and dysfunctional Tregs in Frontotemporal Dementia patients at the AD/PD 2024 Conference. Dr. Alireza Faridar will showcase the role of the immune system in FTD pathology, funded by a grant from Houston Methodist. Coya plans to file an IND for COYA 302, a therapeutic candidate, in 4Q24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
conferences
-
News
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) presents novel biomarker data in ALS patients correlating to disease progression and survival. Dr. Stanley Appel to present at the Society of Neuroimmune Pharmacology Conference on March 12th, 2024, highlighting the potential of the oxidative stress biomarker candidate. The company aims to enhance Treg function with biologics, offering new insights for patient monitoring and therapy efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
-
News
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands COYA 302 pipeline into Alzheimer's Disease, leveraging synergistic mode of action with LD IL-2 and CTLA4-Ig. The partnership with Dr. Reddy's Laboratories in ALS is valued at up to $733 million. Ongoing double-blind trial for LD IL-2 in AD aims to support COYA 302 development. The company plans to file INDs for ALS and FTD in 2024, with additional clinical updates and expansion of combination therapies beyond COYA 302.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
News
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands patent estate with a license from University of Nebraska Medical Center for multiple low dose interleukin-2 (ld IL-2) combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). The combination results in a 4-6 fold synergistic increase in Tregs, enhancing Treg function and lowering inflammation. UNeMed will receive payments and royalties. The license strengthens Coya's multi-pathway approach in developing immunomodulatory drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
none
Stock COYA logo
Coya Therapeutics Inc

Nasdaq:COYA

COYA Rankings

#4089 Ranked by Market Cap
#1884 Ranked by Stock Gains
N/A Ranked by Dividends

COYA Stock Data

131.71M
9.97M
7.95%
17.57%
1.31%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Houston